Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc. (SNDX)
:SNDX
SNDX Stock Chart & Stats
$13.11
$0.12(0.87%)
At close: 4:00 PM EST
$13.11
$0.12(0.87%)
Day’s Range― - ―
52-Week Range$8.58 - $22.50
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.75M
Market Cap
$1.17B
Enterprise Value$698.84M
Total Cash (Recent Filing)$468.71M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 03, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding86,141,860
10 Day Avg. Volume4,087,904
30 Day Avg. Volume2,748,057
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit9.29
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$35.00Price Target Upside166.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Commercial MomentumSyndax has entered a new phase of executional depth as Revuforj advances from its initial launch in relapsed or refractory leukemia toward first-line expansion, with commercial traction already exceeding expectations through rapid formulary access and sustained treatment persistence.
FDA ApprovalRevuforj received FDA approval for the treatment of relapsed or refractory NPM1-mutated AML, expanding its reach into the largest molecularly defined AML subgroup.
Market OpportunityRevumenib now addresses more than 6,500 U.S. relapsed or refractory acute leukemia patients annually, creating a greater than $2B market opportunity.
Bears Say
Investor ConcernsShares traded down approximately 8% due to investor concerns over the expanded boxed warning, though it is not viewed as a significant commercial impediment.
Market ReactionThe reaction is overdone and ultimately unlikely to impact prescribing decisions in the R/R setting with the side effect long associated with Revuforj.
Regulatory UpdatesFDA approved the sNDA for Revuforj for R/R NPM1m AML—but notably added QTc prolongation to the Black Box.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc.’s price range in the past 12 months?
Syndax Pharmaceuticals Inc. lowest stock price was $8.58 and its highest was $22.50 in the past 12 months.
What is Syndax Pharmaceuticals Inc.’s market cap?
Syndax Pharmaceuticals Inc.’s market cap is $1.17B.
When is Syndax Pharmaceuticals Inc.’s upcoming earnings report date?
Syndax Pharmaceuticals Inc.’s upcoming earnings report date is Nov 03, 2025 which is in 5 days.
How were Syndax Pharmaceuticals Inc.’s earnings last quarter?
Syndax Pharmaceuticals Inc. released its earnings results on Aug 04, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.016 by $0.186.
Is Syndax Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc.’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc. pay dividends?
Syndax Pharmaceuticals Inc. does not currently pay dividends.
What is Syndax Pharmaceuticals Inc.’s EPS estimate?
Syndax Pharmaceuticals Inc.’s EPS estimate is -0.73.
How many shares outstanding does Syndax Pharmaceuticals Inc. have?
Syndax Pharmaceuticals Inc. has 86,141,860 shares outstanding.
What happened to Syndax Pharmaceuticals Inc.’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc. reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.016. Following the earnings report the stock price went up 21.098%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in SNDX
Syndax Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.00 (166.97% Upside)
$35.00 (166.97% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 292.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.08%
12-Months-Change
Fundamentals
Return on Equity
-113.22%
Trailing 12-Months
Asset Growth
24.99%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
SNDX Company Deck
SNDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant revenue growth and strategic advancements in pipeline and market expansion. The company shows a clear path to profitability with stable operating expenses and promising future opportunities. However, there are some dependencies on regulatory approvals and expectations for increased transplant rates.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$35.00
▲(166.97% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
14.62% Mutual Funds
2.10% Other Institutional Investors
68.93% Public Companies and Individual Investors